tbuckley/cabot-search huggingface dataset:
Endocrine-Disrupting Chemicals in Cosmetics—Reply
Authors: Courtney Blair Rubin, Bruce A. Brod
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
SINGLE LEAD FOR STEMI DETECTION DOES NOT LOCALIZE OR IDENTIFY CULPRIT LESION
Authors: Sameer Mehta, Francisco Fernandez, Carlos Villagrán, Sebastian Niklitschek, Jorge Ávila, Roberto Botelho, Alejandra Frauenfelder, Daniel Vieira, Mariana Ceschim, Sohail Merchant, Akhil Vaid, Gladys Pinto, Isabella Vallenilla, Genesis Perez Del Nogal, Lilly Prieto, Maritza Luna, Daniela Bou Daher, Samantha Quintero, Juhee Lee
Journal: Journal of the American College of Cardiology (2020)
Offender trajectories, health and hospital admissions: relationships and risk factors in the longitudinal Cambridge Study in Delinquent Development
Authors: Guy CM Skinner, David P Farrington, Jonathan P Shepherd
Journal: Journal of the Royal Society of Medicine (2020)

Research suggests that antisocial lifestyles constitute significant health risks. However, there are marked individual differences in the stability of antisocial behaviour. These different offending pathways may bear differential risks for adult health.Injury and illness data were collected prospectively in the longitudinal Cambridge Study in Delinquent Development.Working-class inner-city area of South London.Participants included the 411 men from the Cambridge Study in Delinquent Development, with interview data collected at ages 18, 32 and 48 years for each individual.Organic illness, hospitalisation and injuries.By age 48, adjusted odds ratios showed that the incidence of organic illness was higher among Life-Course-Persistent, Late-Onset offenders and offenders in general. Based on adjusted odds ratios at age 32, the incidence of hospitalisations was higher for Late-Onset offenders. Adjusted odds ratios at age 48 also showed that the incidence of hospitalisations was higher for all three offender types and offenders in general. Our results also provide evidence that offenders were more likely to suffer injuries than non-offenders.The findings of this study imply that preventing individuals from offending is likely to have substantial benefits for health.
CHRONIC STRUCTURAL EFFECTS OF BIOPSY PROVEN 2R REJECTION IN HEART TRANSPLANT PATIENTS
Authors: Muhannad Abbasi, Roberto Sarnari, Arif Jivan, Julie Blaisdell, Daniel C. Lee, Allen S. Anderson, Kambiz Ghafourian, Sadiya Khan, Esther E. Vorovich, Jonathan Rich, Jane Wilcox, Clyde W. Yancy, James C. Carr, Michael Markl
Journal: Journal of the American College of Cardiology (2020)
INCIDENCE AND DETERMINANTS OF INAPPROPRIATE SHOCK IN HYPERTROPHIC CARDIOMYOPATHY PATIENTS WITH SUBCUTANEOUS IMPLANTABLE DEFIBRILLATORS
Authors: Zack Dale, Andrew Gray, Miriam Elman, Gianmarco Carrassa, Paolo Pieragnoli, Giuseppe Ricciardi, Nosheen Reza, Tuna Ustunkaya, Nikolaos Papoutsidakis, Daniel Jacoby, David S. Frankel, Anjali Owens, Olivotto Iacopo, Stephen B. Heitner, Babak Nazer
Journal: Journal of the American College of Cardiology (2020)
The relation between neutrophil lymphocyte ratio and survival in patients with small cell lung cancer.
Authors: Mevlude Inanc, Oktay Bozkurt, Melih Kiziltepe, Halit Karaca, Veli Berk, Ayse Ocak Duran, Metin Ozkan
Journal: Journal of Clinical Oncology (2013)

e18516 Background: Neutrophil-lymphocyte ratio (NLR) is not an only inflammation marker, but also used as a prognostic index of various malignancies. Small cell lung cancer (SCLC) is considered metastatic at time of diagnosis, and survival is quite short. There is no any study evaluating the relationship between NLR and survival in SCLC. In this study, we aimed to determine the effect of NLR on overall survival. Methods: The study included 200 patients with SCLC. Survival times of patients, clinicopathological data and the results of a complete blood count at diagnosis were evaluated from patient archive files retrospectively. Patients were randomized into two groups according to NLR 5&lt; or 5≥. Results: The median age of patients was 56 (36-80) years. One hundred and eighty one (90.5%) patients were male and 19 (9.5%) were males. Sixty-eight (34%) patients had dyspnea, 36 (18%) of cases had cough, 22 (11%) patients had back pain, and 14 (7%) of the cases had chest pain. While the duration of symptoms longer than 3 months in 90 (45%) patients, 110 (55%) patients had symptoms shorter than 3 months. Seventy-two (36%) patients had limited disease, 128 (64%) patients had extensive disease at the time of diagnosis. Twenty-one (10.5%) patients had brain metastasis initially. The median neutrophil count was 5.46 (1.02-20.2) 10 3 µl, and the median lymphocyte 1.69 (0.27 to 21.9) 10 3 µl, and median NLR was 3.19 (0.04 to 37.63) respectively. NLR overall survival rate was lowering in patients with greater than or equal to 5 group (5 ≥ group=7 months, 5&lt; group=10 months) (p = 0.004). Conclusions: NLR is an important prognostic index that emphasis on the relationship between cancer and host in SCLC. However, a blood test is cheap and easy to use. This study was concluded that survival was shorter in patients with NLR ≥ 5 in SCLC.
Weekly (QW) epoetin alfa (EPO) in prostate cancer (PC) patients (pts) with anemia not receiving chemotherapy (CT) or radiation therapy (RT)
Authors: D. Shasha
Journal: Journal of Clinical Oncology (2006)

14634 Background: While EPO is widely used in the management of CT-related anemia, anemia in cancer pts may stem from causes other than CT. Tumor invasion of the bone marrow and cytokine-mediated inhibition of erythropoiesis are among the many disease-related causes of anemia in cancer. Data evaluating the use of EPO in pts not receiving CT or RT, particularly in specific tumor types, would be important information to healthcare providers. Methods: An open-label, prospective, non-randomized, multicenter pilot study was conducted to evaluate the efficacy and safety of EPO 40,000 U QW in anemic (hemoglobin [Hb] ≤ 11 g/dL) cancer pts not receiving CT or RT 1 . (Blood 2004;104:abstract 4223.) Treatment duration was up to 12 wks with a 4-wk post-treatment observation period. Primary efficacy endpoint was hematopoietic response during the treatment period (% of pts achieving a ≥ 1 or ≥ 2 g/dL Hb increase from baseline [BL]). Secondary endpoints included change from BL in quality of life as measured by the Linear Analog Scale Assessment (LASA). This is a retrospective subset analysis of PC pts (n = 24) enrolled in the prospective study. Results: For the safety population (all pts who received ≥ 1 EPO dose, n = 23), mean age was 71.4 ± 6.8 yrs; 21 (91.3%) had ECOG status of 0 or 1; and mean BL Hb was 10.4 ± 0.8 g/dL. Of 21 pts evaluated for efficacy, 17 (81.0%) achieved Hb increase from BL ≥ 2 g/dL, while 19 (90.5%) achieved ≥ 1 g/dL by wk 17/early withdrawal. EPO dose was increased in 5 (23.8%) pts (to 60,000 U for Hb increase &lt; 1 g/dL after 4 wks) and held in 16 (76.2%) pts (due to Hb &gt; 13 g/dL, with dosing resumed when Hb was ≤12 g/dL, at 30,000 U from 40,000 U or at 40,000 U from 60,000 U). Both Wk 9 and 17 LASA scores increased significantly from BL in all categories (Energy Level, Daily Activities, and Quality of Life; P &lt; 0.001). 15 of 23 pts (65.2%) had at least one adverse event (AE); 4 (17.4%) pts had at least one serious AE. No clinically relevant thrombotic vascular events were noted. No pt received transfusion. 5 pts discontinued: 2 for AEs, 1 at pt request, and 2 at study sponsor request. Conclusions: This retrospective analysis suggests that EPO 40,000 U QW is safe and effective for treating anemia in PC pts not receiving CT or RT. [Table: see text]
Retrospective cohort study on the safety and efficacy of cetuximab for metastatic colorectal cancer patients: The HGCSG0901 study—Analysis of cetuximab refractory.
Authors: Satoshi Yuki, Yoshito Komatsu, Yasuyuki Kawamoto, Yasushi Tsuji, Hirohito Naruse, Ayumu Hosokawa, Takaya Kusumi, Atsushi Ishiguro, Soh Saitoh, Yuh Sakata
Journal: Journal of Clinical Oncology (2012)

639 Background: In the NCIC CTG CO.17 trial comparing in the Best Supportive Care (BSC) and cetuximab (Cmab) monotherapy for patients as third line treatment, median survival time (MST) of patients assigned to BSC was 4.8 months in the wild-type KRAS, and 4.6 months in the KRAS mutant.In contrast, MST of patients assigned to Cmab in the same trial was 6.1 months, and median progression-free survival (mPFS) was 1.9 months, so the difference (Survival Beyond Progression: SBP) between MST and mPFS was about four months. From past reports, the prognosis after 3rd line and later Cmab refractory was very poor. We performed survival analysis of after Cmab refractory. Methods: Of 269 cases registered in the multi-institutional retrospective study (HGCSG0901) treated with Cmab, 233 patients for Cmab refractory of 3rd line or after treatment line were analyzed. Overall survival after Cmab refractory for patients for 3rd line or after treatment line were evaluated for association with prognostic factors such as presence of peritoneal dissemination, the number of metastatic organs, Albumin, ALP, CEA, CA19-9 at the time of Cmab refractory, KRAS mutational status, chemotherapy after Cmab refractory using univariate and multivariate Cox proportional hazard model. Results: MST after refractory for patients with Cmab administration after 3rd line treatment was 4.3 months, which was comparable with SBP of previous clinical trials. Results of multivariate analysis suggested that, PS, presence of peritoneal dissemination, the number of metastatic organs, Albumin, ALP at the time of Cmab refractory and chemotherapy (both already refractory drug only and non refractory drug included) after Cmab refractory were independent prognostic factors after Cmab refractory. Conclusions: PS, presence of peritoneal dissemination, the number of metastatic organs, Albumin, ALP at the time of Cmab refractory and chemotherapy after Cmab refractory should be regarded as an important factor for prognosis after Cmab refractory in colorectal cancers.
Bcl6 and Blimp1 reciprocally regulate ST2+ Treg–cell development in the context of allergic airway inflammation
Authors: Byunghee Koh, Benjamin J. Ulrich, Andrew S. Nelson, Gayathri Panangipalli, Rakshin Kharwadkar, Wenting Wu, Markus M. Xie, Yongyao Fu, Matthew J. Turner, Sophie Paczesny, Sarath Chandra Janga, Alexander L. Dent, Mark H. Kaplan
Journal: Journal of Allergy and Clinical Immunology (2020)
SHORT-TERM EFFECTS OF AIR POLLUTION ON BLOOD PRESSURE
Authors: You-Jung Choi, Sun-Hwa Kim, Si-Hyuck Kang, Ok-Jin Kim, Sun-Young Kim, Chang-Hwan Yoon, Hae-Young Lee, Tae-Jin Youn, In-Ho Chae, Cheol-Ho Kim
Journal: Journal of the American College of Cardiology (2020)
Bisphosphonates for Osteopenia in Postmenopausal Women—Reply
Authors: Kristine E. Ensrud, Carolyn J. Crandall
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
Authors: Stephanie Bialek, Ellen Boundy, Virginia Bowen, Nancy Chow, Amanda Cohn, Nicole Dowling, Sascha Ellington, Ryan Gierke, Aron Hall, Jessica MacNeil, Priti Patel, Georgina Peacock, Tamara Pilishvili, Hilda Razzaghi, Nia Reed, Matthew Ritchey, Erin Sauber-Schatz
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Globally, approximately 170,000 confirmed cases of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) have been reported, including an estimated 7,000 deaths in approximately 150 countries (1). On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic (2). Data from China have indicated that older adults, particularly those with serious underlying health conditions, are at higher risk for severe COVID-19-associated illness and death than are younger persons (3). Although the majority of reported COVID-19 cases in China were mild (81%), approximately 80% of deaths occurred among adults aged ≥60 years; only one (0.1%) death occurred in a person aged ≤19 years (3). In this report, COVID-19 cases in the United States that occurred during February 12-March 16, 2020 and severity of disease (hospitalization, admission to intensive care unit [ICU], and death) were analyzed by age group. As of March 16, a total of 4,226 COVID-19 cases in the United States had been reported to CDC, with multiple cases reported among older adults living in long-term care facilities (4). Overall, 31% of cases, 45% of hospitalizations, 53% of ICU admissions, and 80% of deaths associated with COVID-19 were among adults aged ≥65 years with the highest percentage of severe outcomes among persons aged ≥85 years. In contrast, no ICU admissions or deaths were reported among persons aged ≤19 years. Similar to reports from other countries, this finding suggests that the risk for serious disease and death from COVID-19 is higher in older age groups.
A comparative analysis of recent HIV outbreaks among people who inject drugs in Europe, North America and Israel
Authors: Don C. Des Jarlais, Vana Sypsa, Jonathan Feelemyer, Adrian Octavian Abagiu, Vic Arendt, Dita Broz, Daniel Chemtob, Carole Seguin-Devaux, Joan M. Duwve, Margaret Fitzgerald, David J. Goldberg, Angelos Hatzakis, Raluca E. Jipa, Eugene Katchman, Eamon Keenan, Ibrahim Khan, Stephanie Konrad, Andrew McAuley, Stuart Skinner, Lucas Wiessing
Journal: The Lancet HIV (2020)
Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma
Authors: Yong Li, Yingqiu Song, Pindong Li, Mingxing Li, Haizhou Wang, Tao Xu, Xiongjie Yu, Yuandong Yu, YunYan Tai, Ping Chen, Xiaojun Cai, Xianhe Wang, Longchao Xiang, Rui Deng, Xiufang Zhang, Liping Gao, Xuanbin Wang, Jing Liu, Fengjun Cao
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Interferon-α (IFN-α) plays a pivotal role in host antitumor immunity, and the evasion of IFN-α signaling pathway can lead to IFN-α resistance during the treatment of cancer. Although the interplay between IFN-α and tumor cells has been extensively investigated in differentiated tumor cells, much less attention has been directed to tumor-repopulating cells (TRCs). Methods Three-dimentional soft fibrin matrix was used to select and grow highly malignant and tumorigenic melanoma TRCs. The regulation of integrin β3 (ITGB3)-c-SRC-STAT signaling pathway in melanoma TRCs was investigated both in vitro and in vivo. The relevant mRNA and protein expression levels were analyzed by qRT-PCR and western blot analysis. Immunoprecipitation and chromatin immunoprecipitation (ChIP) followed by qPCR (ChIP-qPCR) assays were performed to detect protein-protein and protein-DNA interactions. The clinical impacts of retinoic acid inducible gene-I (RIG-I) were assessed in melanoma datasets obtained from The Cancer Genome Atlas and Gene Expression Omnibus profiles. Results IFN-α-induced apoptosis was decreased in melanoma TRCs. Compared with conventional flask-cultured cells, IFN-α-mediated STAT1 activation was diminished in melanoma TRCs. Decreased expression of RIG-I in melanoma TRCs led to diminished activation of STAT1 via enhancing the interaction between Src homology region 2 domain-containing phosphatase-1 and STAT1. In addition, low expression levels of RIG-I correlated with poor prognosis in patients with melanoma. STAT3 was highly phosphorylated in TRCs and knockdown of STAT3 reversed the downregulation of RIG-I in TRCs. Knockdown of STAT3 resulted in STAT1 activation and increased expression of the pro-apoptosis genes in IFN-α-treated TRCs. Combined treatment of STAT3 inhibitor and IFN-α increased the apoptosis rate of TRCs. Disruption of ITGB3/c-SRC/STAT3 signaling pathway significantly elevated the efficiency of IFN-α-induced apoptosis of TRCs. Conclusions In melanoma TRCs, ITGB3-c-SRC-STAT3 pathway caused RIG-I repression and then affect STAT1 activation to cause resistance to IFN-α-induced apoptosis. RIG-I is a prognostic marker in patients with melanoma. Combination of STAT3 inhibitor and IFN-α could enhance the efficacy of melanoma treatment. Our findings may provide a new concept of combinatorial treatment for future immunotherapy.
Safety of asparaginase <i>Erwinia chrysanthemi</i> in a compassionate-use trial: Subanalysis of the adolescent/young adult (AYA) and adult patient (Pt) population.
Authors: Paul V. Plourde, Sima Jeha, Nobuko Hijiya, Frank G. Keller, Susan R. Rheingold, Zoann Dreyer, Gary V. H. Dahl, Taheri Mercedes, Tim Corn
Journal: Journal of Clinical Oncology (2013)

7097 Background: The AYA population is usually defined as pts aged 16 to 39 years. NCCN guidelines recommend that AYA patients with acute lymphoblastic leukemia (ALL) be treated with ‘pediatric-inspired’ protocols that includeL-asparaginase (L-ASP) as an integral component of their multiagent chemotherapy regimen. Hypersensitivity reaction is the most common toxicity associated with L-ASP treatment, occurring in 10%–30% of pts treated with E coli–derived L-ASP, necessitating its discontinuation. In those pts, it is recommended that L-ASP derived from Erwinia chrysanthemi (Erw) be initiated since it is immunologically distinct from E coli–derived L-ASP. Methods: A large compassionate-use trial in pts with ALL or lymphoblastic lymphoma who developed a hypersensitivity reaction (ie, grade ≥2) to an E coli–derived L-ASP was conducted to evaluate the safety of Erw. Pts were excluded if they had a history of pancreatitis, previous allergic reaction to Erw, or were pregnant. Adverse events (AEs) and/or case report forms were completed for 940 pts. The Erw safety information for the full study population was previously reported. Here, we report a safety analysis of pts aged ≥16 years with the majority being AYA (94%), a population in which little Erw safety information has been presented. Results: In this compassionate-use trial, 156 pts were aged ≥16 years. These pts were primarily male (67.9%), had nonrelapsed disease (70.5%), B-lineage ALL (71.2%), and received intramuscular Erw (85.9%). 71.8% completed their planned Erw course. Reasons for discontinuation included allergic reaction (3.2%), other AEs (9.6%), other reasons (6.4%), and unknown reasons (9%). Hypersensitivity occurred in 20 (12.8%); hyperglycemia, 9 (5.8%); pancreatitis, 6 (3.8%); thrombosis, 5 (3.2%); bleeding, 1 (1%). Grade 3/4 AEs with a &gt;5% incidence included hyperglycemia (5.8%). There were 10 deaths: 4 disease progression, 3 infection, 1 coma, 1 renal impairment, 1 unknown. Conclusions: The safety profile of Erw in pts ≥16 years was consistent with the profile in the entire study population. This compassionate-use trial permitted the completion of L-ASP in 71.8% of AYA and adult pts. Clinical trial information: NCT00693602.
DYNAMIC CONFORMATIONAL CHANGES OF THE LEFT VENTRICULAR OUTFLOW TRACT COMPARED TO THE AORTIC ANNULUS AND IMPLICATIONS ON TRANSCATHETER AORTIC VALVE SELECTION AND SIZING
Authors: Ahmad O. Aljamal, Yusuf Alalwan, Nicholas Coriasso, Courtnay Hughes, Elsheikh Abdelrahim, James Chihong Lee, Dee Dee Wang, Milan Pantelic, Thomas Song, Marvin Eng, Tiberio M. Frisoli, Pedro Villablanca, Janet Fredal Wyman
Journal: Journal of the American College of Cardiology (2020)
Conditional survival probability for head and neck squamous cell cancer: Results from the SEER 11 Dataset
Authors: C. D. Fuller, S. J. Wang, J. W. Goldwein, C. R. Thomas, R. S. Weber, H. T. Hoffman, D. I. Rosenthal
Journal: Journal of Clinical Oncology (2006)

5519 Background: Survival for most cancers is typically reported as a 5-yr percentage from the time of diagnosis. Surviving patients e.g., desire to know if their likelihood for survival has improved, given that they have lived X-years since diagnosis. Conditional survival (CS) is a calculated probability of survival that demonstrates the changing likelihood of demise during a span of intervals after diagnosis. The specific aim of this study is to assess the CS for patients with head and neck squamous cell carcinoma (HNSCC). Methods: The study population included HNSCC patients from the Surveillance, Epidemiology, and End Results (SEER 11) Program. Cumulative survival rates were calculated using JMP v6 (SAS, Cary, NC) with the product-limit method, and derived on the basis of the subsequent annual survival data. Results were also sub-stratified by site of disease. Results: 90,526 patients with histologically confirmed HNSCC diagnosed from 1973 to 2001 were included. The cumulative HNSCC crude cohort 5-year CS at diagnosis is 33%, and 38% at one-year after diagnosis. 5-year CS is 43% at 2 years post-diagnosis, where it plateaus for the next 8 one-year intervals. Sub-site analysis reveals similar CS trends for all HNSCC sites except the nasopharynx. Nasopharynx cancer CS, in contrast, progressively increases over all intervals. Conclusions: HNSCCC 5-year mortality risk stabilizes within 2–3 years after diagnosis, and with the exception of nasopharyngeal cancers, does not substantially improve thereafter. The SEER data represent the largest pooled dataset for HNSCC, but do not necessarily address all relevant issues contributing to risk for death. These data, however, do provide useful estimates for HNSCC patients with known survival after diagnosis, and may have utility in the design of clinical trials which incorporate survival modeling. [Table: see text] No significant financial relationships to disclose.
Dermoscopic predictors to discriminate between in situ and early invasive lentigo maligna melanoma: A retrospective observational study
Authors: Leonardo Peruilh-Bagolini, Zoe Apalla, Ruben González-Cuevas, Konstantinos Lallas, Chryssoula Papageorgiou, Mattheos Bobos, Sofia Magdalini Manoli, Theodosia Gkentsidi, Ioannis Spyridis, Elizabeth Lazaridou, Elena Sotiriou, Efstratios Vakirlis, Dimitrios Ioannides, Aimilios Lallas
Journal: Journal of the American Academy of Dermatology (2020)